Brief: Xspray Q1 Revenue SEK 0
08/05/2024 07:00
May 08 (Reuters) - Xspray Q1 adjusted EPS SEK -2.17. * Q1 adjusted free cash flow SEK -55.311 million * Q1 pretax profit SEK -67.781 million
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003